Efficacy and safety of IPX203 in Parkinson's patients: a systematic review and meta-analysis.

BACKGROUND

Parkinson's disease (PD) is one of the most common neurodegenerative disorders, characterized by motor symptoms in addition to non-motor symptoms that significantly impact the quality of life. While levodopa remains the gold standard for PD treatment, chronic use is associated with motor complications, including the "wearing-off" phenomenon and dyskinesia. IPX203, a novel extended-release carbidopa-levodopa (CD-LD) formulation, combines immediate-release granules with extended-release effects to maintain therapeutic plasma levels longer, potentially improving motor symptom management for PD patients.

METHODS

A computer literature search of PubMed, Scopus, Web of Science, Google Scholar, and Cochrane Library was conducted using relevant keywords. Records were screened for eligible studies and data were extracted and synthesized using Review Manager version 4.5 for Windows. Sensitivity analysis was conducted to investigate the efficacy of IPX203 against IR CD-LD.

RESULTS

Four RCTs with a total of 712 patients were eligible for the final analysis. The mean difference (MD) of change in the main outcomes from baseline to endpoint favored IPX203 over IR CD-LD (UPDRS) (MD = -6.80, 95% CI: [-9.38, -4.23]; p < 0.00001). change in the off time favored IPX203 over IR CD-LD after sensitivity analysis (MD = -2.42, 95% CI: [-3.12, -1.71]; P < 0.00001). The mean difference (MD) of change in the " good on" time favored IPX203 over IR CD-LD after sensitivity analysis (MD = 2.15, 95% CI: [1.45, 2.86]; P < 0.00001). None of the adverse events were significantly higher in the case of IPX203 compared to IR CD-LD.

CONCLUSION

IPX203 shows a significant potential in improving motor functions, reducing "off" time while increasing "good on" time. This makes IPX203 a valuable addition to current PD treatment strategies.